Manufacturer of Valganciclovir/Valganciclovir

The main manufacturer of Valcyte/Valganciclovir is Switzerland's Roche Pharmaceutical Company (Hoffmann-La Roche Limited), with the trade name Valcyte. Roche's Valganciclovir is patent protected and is sold and distributed worldwide.

As one of the world's leading pharmaceutical companies, Roche Pharmaceuticals has outstanding capabilities and rich experience in drug R&D and production. Valganciclovir produced by this company was approved for marketing in the United States by the U.S. Food and Drug Administration (FDA) in 2001. Subsequently, it was approved for marketing by the National Medical Products Administration in China in 2019. Domestic imports mainly come from Patheon Inc, a Canadian pharmaceutical company, which provides important treatment options for patients and organ transplant patients around the world.

Valganciclovir is theL-valyl ester of ganciclovir, which when broken down by the intestines and liver into ganciclovir, works by preventing or slowing the spread of cytomegalovirus (CMV) disease. /span>CMV is indicated for the treatment of cytomegalovirus retinitis in adult patients with acquired immunodeficiency syndrome (AIDS) and the prevention of cytomegalovirus disease in adult and pediatric solid organ transplant patients at risk for infection.

Common side effects of valganciclovir include abdominal pain, headache, insomnia, nausea, fever, and low blood counts. Other side effects may include infertility and kidney problems. When used during pregnancy, it can cause birth defects in some animals. When using this drug, patients should strictly follow the doctor's recommendations and prescription instructions, and pay attention to the method of use, dosage and possible side effects of the drug.